Neos Therapeutics, Inc. (NASDAQ:NEOS) is set to announce second quarter earning results on Monday 10th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, NEOS to report 2Q20 loss of $ 0.13 per share.
For the full year, analysts anticipate top line of $ 66.37 million, while looking forward to loss of $ 0.3 per share bottom line.
Previous Quarter Performance
Neos Therapeutics, Inc. communicated loss for the first quarter of $ 0.16 per share, from the revenue of $ 14.49 million. The quarterly earnings declined 81.56 percent while revenues compared with the same quarter last year.
Wall street analysts are predicting, NEOS to report 1Q20 loss of $ 0.09 per share from revenue of $ 14.55 million. The bottom line results missed street analysts by $ 0.07 or 77.78 percent, at the same time, top line results fell short of analysts by $ 0.06 million or 0.41 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Neos Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of NEOS was $ 0.72, representing a 20.00 % increase from the 52 week low of $ 0.60 and a 66.51 % decrease over the 52 week high of $ 2.15.
The company has a market capital of $ 35.82 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”NEOS” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Neos Therapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.neostx.com
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold.
